PRME (Prime Medicine) Tariff Resilience Score: 8/10 (As of Jun. 26, 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.43
! 4 Warning Signs
View Full Analysis

What is Prime Medicine Tariff Resilience Score?

Prime Medicine PRME +8.03% 25 Tariff Resilience Score is 8 as of Jun. 26, 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,378 Biotechnology companies, Prime Medicine ranks better than 98.69% on this metric.

Prime Medicine has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Prime Medicine has Biotechnology firm with limited direct exposure to tariffs. Primarily affected by regulatory environments rather than trade policies.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Prime Medicine might have Highly Resilient.

Prime Medicine  (NAS:PRME) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Prime Medicine Tariff Resilience Score Related Terms

PRME vs IMMX, SGP, ACRS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Prime Medicine's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Tariff Resilience Score falls into.


PRME
25GF Score
Prime Medicine Inc PRME
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Prime Medicine (PRME) has a Tariff Resilience Score of 8 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Prime Medicine ranks #18 out of 1378 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Prime Medicine's Tariff Resilience Score too high?
Prime Medicine's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Prime Medicine's value of 8 is 100% above this industry median. Based on the distribution chart, Prime Medicine ranks #18 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Tariff Resilience Score compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #18 out of 1378 companies for Tariff Resilience Score. This places Prime Medicine in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Prime Medicine's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Prime Medicine (PRME), the current Tariff Resilience Score is 8 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.43
Price